Search results for "Type 2"

showing 10 items of 1034 documents

Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study.

2012

International audience; PURPOSE: To compare pure molecular diffusion, D, perfusion-related diffusion, D*, and perfusion fraction, f, determined from diffusion-weighted (DW) magnetic resonance (MR) imaging on the basis of the intravoxel incoherent motion (IVIM) theory in patients with type 2 diabetes with and without liver steatosis. MATERIALS AND METHODS: This prospective study was approved by the appropriate ethics committee, and written informed consent was obtained from all patients. Between December 2009 and September 2011, 108 patients with type 2 diabetes (51 men, 57 women; mean age, 50 years) underwent 3.0-T single-voxel point-resolved proton MR spectroscopy of the liver (segment VII…

MaleCirrhosisMagnetic Resonance SpectroscopyMESH : Fatty Liver[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingMESH : AgedMESH : Prospective Studies030218 nuclear medicine & medical imagingMESH: Linear Models0302 clinical medicineNuclear magnetic resonanceMESH: Aged 80 and overMESH : Diabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseMESH : Linear ModelsNonalcoholic fatty liver diseaseMESH : FemaleProspective StudiesMESH: Fatty LiverIntravoxel incoherent motion[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overMESH: AgedMESH: Statistics NonparametricMESH: Middle Aged[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingFatty liverMiddle AgedMESH : AdultMESH : Diffusion Magnetic Resonance Imaging3. Good health030220 oncology & carcinogenesisPotential confounderFemaleRadiologyMESH: Diabetes Mellitus Type 2Adultmedicine.medical_specialtyMESH : MaleMESH: Diffusion Magnetic Resonance ImagingStatistics Nonparametric03 medical and health sciencesmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingMESH : Middle AgedMESH : Aged 80 and overMESH : Statistics NonparametricAgedMESH: Humansbusiness.industryMESH: Magnetic Resonance SpectroscopyMESH : HumansMESH: Biological MarkersMESH: Adultmedicine.diseaseMr imagingMESH: MaleMESH: Prospective StudiesFatty LiverMESH : Biological MarkersDiffusion Magnetic Resonance ImagingDiabetes Mellitus Type 2Linear ModelsMESH : Magnetic Resonance SpectroscopySteatosisbusinessMESH: FemaleBiomarkersDiffusion MRI
researchProduct

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pi…

2015

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode …

MaleClinical BiochemistryPilot ProjectsType 2 diabetesCarotid Intima-Media ThicknessGastroenterologychemistry.chemical_compoundRisk FactorsDrug DiscoveryProspective StudiesProspective cohort studyliraglutideMedicine (all)Fatty liverLipidMiddle AgedLipidsHemoglobin AAtherosclerosiFemalemedicine.drugHumanmedicine.medical_specialtycarotid intima-media thickneInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsPilot ProjectAgedGlycated HemoglobinHemoglobin A GlycosylatedPharmacologytype 2 diabeteHypoglycemic AgentLiraglutidebusiness.industryRisk FactorDrug Discovery3003 Pharmaceutical Sciencenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseAtherosclerosismedicine.diseaseProspective StudieEndocrinologychemistryIntima-media thicknessDiabetes Mellitus Type 2Glycated hemoglobinbusiness
researchProduct

Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras

2021

Aim The aim of this study was to analyze changes in the incidence, management and mortality of DFU in Sicilian Type 2 diabetic patients hospitalized between two eras, i.e. 2008–2013 and 2014–2019. Methods We compared the two eras, era1: 2008–13, era2: 2014–19. In era 1, n = 149, and in era 2, n = 181 patients were retrospectively enrolled. Results In the population hospitalized for DFU in 2008–2013, 59.1% of males and 40.9% of females died, whilst in 2014–2019 65.9% of males and 34.1% of females died. Moderate chronic kidney disease (CKD) was significantly higher in patients that had died than in ones that were alive (33% vs. 43%, p < 0.001), just as CKD was severe (14.5% vs. 4%, p <…

MaleComorbidityAntiplatelet TherapyBiochemistrySettore MED/13 - EndocrinologiaEndocrinologyMedical ConditionsOral DiseasesRetrospective StudieChronic Kidney DiseaseMedicine and Health SciencesSurgical AmputationInsulinSicilyUlcersAged 80 and overMultidisciplinaryPharmaceuticsIncidenceQRMiddle AgedDiabetic FootType 2 DiabetesHospitalizationNephrologyMedicineFemaleHumanResearch ArticleEndocrine DisordersScienceOral MedicineSurgical and Invasive Medical ProceduresSigns and SymptomsLife ExpectancyDrug TherapyDiabetes MellitusRenal DiseasesHumansMortalityRenal Insufficiency ChronicAgedRetrospective StudiesDiabetic EndocrinologyBiology and Life SciencesHormonesDiabetes Mellitus Type 2Metabolic DisordersClinical MedicinePLoS ONE
researchProduct

'I saw what the future direction would be...' : Experiences of diabetes risk and physical activity after diabetes screening

2015

Objectives To improve understanding of how individuals at high risk of type 2 diabetes experience the risk of diabetes and how these experiences relate to the adoption of physical activity as a protective behaviour. Design A qualitative study using semi-structured interview with individuals identified by screening as at high risk of type 2 diabetes. Methods Fourteen individuals, aged 40–64, were interviewed twice, with a 2-year interval between. Participants' experiences of their risk of diabetes and physical activity were assessed. The transcribed interview data were analysed using inductive qualitative content analysis. Results Two themes emerged from the data: a threatening risk percepti…

MaleCoping (psychology)Health Knowledge Attitudes Practicegenetic structuresHealth Behaviorphysical activityType 2 diabetesBody Mass Index0302 clinical medicineexperienceprevention030212 general & internal medicineta315Applied PsychologyFinlandQualitative Researchmedia_commonta3141CognitionGeneral MedicineMiddle Agedperceived riskAnxietyFemaletype 2 diabetesmedicine.symptomPsychologyClinical psychologyAdultRiskDiabetes riskmedia_common.quotation_subjectehkäisy030209 endocrinology & metabolismbehaviour changeInterviews as Topic03 medical and health sciencesPerceptionmedicineHumansExerciseLife StyleMotivationscreeningmedicine.diseaseRisk perceptionDiabetes Mellitus Type 2Qualitative researchFollow-Up Studies
researchProduct

Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian S…

2011

Abstract Background The Visceral Adiposity Index (VAI) is a sex-specific mathematical index, based on Waist Circumference (WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral adipose function and insulin sensitivity. Our aim was to find the optimal cut-off points of VAI identifying a visceral adipose dysfunction (VAD) associated with cardiometabolic risk in a Caucasian Sicilian population. Methods Medical check-up data of 1,764 Primary Care patients (PC patients) were retrospectively and cross-sectionally examined using a receiver-operating characteristic (ROC) curve to determine appropriate stratified-for-age cut-off of VAI, for t…

MaleCross-sectional studyEndocrinology Diabetes and MetabolismClinical BiochemistrySettore MED/13 - EndocrinologiaEndocrinologyReference ValuesRisk Factorscardiometabolic riskPrevalenceMyocardial infarctionSicilylcsh:RC620-627Aged 80 and overMetabolic Syndromeeducation.field_of_studyMiddle Agedlcsh:Nutritional diseases. Deficiency diseasesCardiovascular DiseasesCardiologyvisceral adipose dynsfunctionFemaleAdultmedicine.medical_specialtyWaistAdolescentPopulationVisceral adiposity index VAI Obesity cardiometabolic risk visceral adipose dynsfunctionClinical nutritionIntra-Abdominal FatWhite PeopleYoung AdultInternal medicineDiabetes mellitusmedicineHumansBody Weights and MeasuresObesitycardiovascular diseaseseducationAgedRetrospective StudiesBiochemistry medicalbusiness.industryResearchBiochemistry (medical)medicine.diseaseVAIEndocrinologyCross-Sectional StudiesDiabetes Mellitus Type 2Metabolic syndromebusinessBody mass indexLipids in Health and Disease
researchProduct

Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis …

2018

This study cross-sectionally examines in the elderly population: (a) the association of type 2 diabetes with executive function (EF); (b) the effect of BMI on both type 2 diabetes and EF; (c) the association between glycaemia control and EF in type 2 diabetes. 6823 older individuals with overweight/obesity and metabolic syndrome participating in the PREDIMED-PLUS study, were assessed with a battery of cognitive tests and a medical interview. ANOVA showed a significantly worse performance on EF in type 2 diabetes vs. non-diabetic individuals. Two complementary models were displayed: (1) in the whole sample, the presence of type 2 diabetes, depressive symptoms and BMI had a direct negative ef…

MaleCross-sectional studyhumanosType 2 diabetesOverweightPersones gransBody Mass Index0302 clinical medicineOlder people diseasesMedicine030212 general & internal medicineDiabetes Treatment AdherenceCognitive declineMalalties de les persones gransmediana edad2. Zero hungerMetabolic SyndromeancianoMultidisciplinaryDiabetisCognitive ageingQDiabetesRType 2 diabetesMiddle Aged3. Good healthNeurologydiabetes mellitusMedicineObesitatFemalemedicine.symptomPREDIMEDmedicine.medical_specialtyMedicinaScienceArticle03 medical and health sciencesOlder populationDiabetes mellitusInternal medicineApnoeaHumansCognitive DysfunctionObesityobesidadAgedGlycated Hemoglobinbusiness.industryíndice de masa corporalBaseline Cross-sectional AnalysisCognitive neuroscienceCognitive Function PerformanceOverweightmedicine.diseaseObesityCross-Sectional StudiesDiabetes Mellitus Type 2StudyMetabolic syndromeOlder peoplebusinessBody mass index030217 neurology & neurosurgeryestudios transversalesGlycaemic Control
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct

Egg consumption and cardiovascular disease according to diabetic status: The PREDIMED study.

2015

BACKGROUND: Eggs are a major source of dietary cholesterol and their consumption has been sometimes discouraged. A relationship between egg consumption and the incidence of cardiovascular disease (CVD) has been suggested to be present exclusively among patients with type2 diabetes. AIMS: To assess the association between egg consumption and CVD in a large Mediterranean cohort where approximately 50% of participants had type 2 diabetes. METHODS: We prospectively followed 7216 participants (55-80 years old) at high cardiovascular risk from the PREDIMED (PREvención con DIeta MEDiterránea) study for a mean of 5.8 years. All participants were initially free of CVD. Yearly repeated measurements o…

MaleDiabetic CardiomyopathiesEggsHealth StatusSistema cardiovascular -- MalaltiesType 2 diabetes030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineDiet MediterraneanCohort Studies0302 clinical medicineRisk FactorsDiet Diabetic030212 general & internal medicineProspective StudiesProspective cohort studyDiet Fat-RestrictedAged 80 and overOusNutrition and DieteticsDiabetisMediterranean RegionIncidence (epidemiology)IncidenceHazard ratioDiabetesMiddle AgedCardiovascular diseaseCardiovascular DiseasesCohortFemaleCohort studymedicine.medical_specialty03 medical and health sciencesDiabetes mellitusInternal medicinemedicineHumansEgg consumptionAgedProportional Hazards ModelsProportional hazards modelbusiness.industryPREDIMED studymedicine.diseaseEndocrinologyDiabetes Mellitus Type 2Patient ComplianceSelf ReportbusinessDiabetic AngiopathiesFollow-Up Studies
researchProduct

The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy.

2002

Topical treatment with capsaicin cream has been shown to be successful in the treatment of different symptomatic nerve disorders like diabetic neuropathy. Conflicting data exist on the effect of capsaicin on nerve function and neurovascular control especially in patients with diabetic neuropathy. The aim of this pilot study was to investigate the impact of topical capsaicin application on small nerve fibre function and neurovascular control. Capsaicin cream was applied to the feet of 13 patients with symptomatic diabetic neuropathy over a period of 8 weeks. Before and during the treatment period, we investigated the total symptoms score, the vibration, thermal (heat and cold) and pain perce…

MaleDiabetic neuropathyEndocrinology Diabetes and MetabolismAdministration TopicalSubstance PPilot Projectschemistry.chemical_compoundRoute of administrationEndocrinologyNerve FibersDiabetic NeuropathiesInternal MedicineMedicineHumansbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseNeurovascular bundlePeripheral neuropathymedicine.anatomical_structureDiabetes Mellitus Type 1chemistryDiabetes Mellitus Type 2CapsaicinAnesthesiaSensory ThresholdsNociceptorFemaleCapsaicinbusinessSensory nervePhytotherapyActa diabetologica
researchProduct

Patients with coronary artery disease and diabetes need improved management : a report from the EUROASPIRE IV survey: a registry from the EuroObserva…

2015

Background: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. Methods: A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabet…

MaleEUROASPIRE InvestigatorsCardiac & Cardiovascular SystemsCross-sectional studyEndocrinology Diabetes and MetabolismAngiotensin-Converting Enzyme InhibitorsBlood PressureCoronary Artery DiseaseType 2 diabetesGUIDELINESCoronary artery diseaseMELLITUSRisk FactorsGlycaemic controlMedicine and Health SciencesSecondary PreventionCoronary artery disease ; Type 2 diabetes ; Secondary prevention ; Management ; Guideline adherence ; Blood lipids ; Blood pressure ; Glycaemic controlCardiac and Cardiovascular SystemsRegistriesMyocardial infarctionGLUCOSE CONTROLOriginal InvestigationBLOOD-GLUCOSEType 2 diabetesMiddle AgedManagementEuropeglycaemic controlHypertensionPractice Guidelines as TopicHEARTPlatelet aggregation inhibitorFemaletype 2 diabetesGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemanagementmedicine.medical_specialtyCardiotonic AgentsAdrenergic beta-Antagonists/Endocrinology and Diabetes1102 Cardiovascular Medicine And HaematologyEndocrinology & MetabolismAngiotensin Receptor AntagonistsSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentsddc:610Risk factorAntihypertensive AgentsAgedDyslipidemiasScience & Technologyblood lipidsbusiness.industryMORTALITYCholesterol LDLmedicine.diseaseCross-Sectional StudiesBlood pressureCardiovascular System & HematologyMYOCARDIAL-INFARCTIONDiabetes Mellitus Type 2Cardiovascular System & CardiologyBlood lipidsCARDIOVASCULAR-DISEASESRISK-FACTORSHydroxymethylglutaryl-CoA Reductase InhibitorsFOLLOW-UPbusinessPlatelet Aggregation Inhibitors
researchProduct